Intellectual Property
Minneapolis/St. Paul
Marking a Product
NDAs and Customers
Consequences of Disclosing Confidential Information
How is Open Source Incorporated into Software?
What is Prior Art?
Background
Unanticipated OSS
Merrifield Synthesis
Forms of Confidential Information
Cited Art Landscape
Should IP be Part of Our Business Plan?
Freedom to Operate
Post-Grant Options
Freedom To Operate
Specimen
Genericide
Categories of Marks
Open Source Software
Joint Ventures and Dispute Resolution
Meet David Black
Portfolio Mapping
OSS Licensing Conditions
Why Is Executing an NDA Not Enough?
Importance of Getting a Patent
Joint Venture Pitfalls
Mitigating Risks of Past Damages
Reasons to Consider Joint Ventures
What to Do When First Selecting a Mark
How do Patent Prosecution Services Vary in Value?
The Case of the Joint Marketing Agreement Gone Bad
Determining Likelihood of Confusion
First Item on IP To-Do List
4 Ways to Prepare your Patent Portfolio for Battle.
Litigation Density
Patent Status Updates
Portfolio Dashboard - Inventor Information
BioSimilar Patenting Litigation Involving Large Amounts of Money
Hiring Patent Council
Importance of Freedom To Operate
Common Law Trademark Rights
Segmenting a Portfolio
Licensing Density
How is Open Source Software Enforced?
Trade Secrets
By the Numbers Overview
Prior Art and Rejections
Implementing a Value-Driven Portfolio Process
What is an Invention?
Patents 101
Post-Litigation Challenges
Importance of Post-Grant Proceedings
Low Risk Joint Ventures
Value Management Lifecycle
Patent Profile Analytics and Managers
Geographic Insight and Patent Profile Analytics
Freedom to Operate (FTO) Process
Covered Business Method Review
Interpretational Differences Between Prosecution and Litigation
How to Fix the Knowledge Gap
"Whens" - Audit Action Sheet
The Five Components of an Open Source Software Policy
Scope Concepts and Headnotes
What Engineers Can Learn from Patent Profile Analytics
Unlicensed Source Codes
Trademark Filing Considerations
A Better Way to Allocate Patent Application Budgets
Limited Valuable Patents in Technology Area
Inventorship
Forward Citation Landscape
Approvals of BioSimilars in Europe
What is a BioSimilar?
Prior Art in Prosecution vs Prior Art in Litigation
"Wheres" - Audit Action Sheet
Confidential Information and Business Damage
Who Determines Substitution Factors?
What Should a Company Patent?
Am I Required to Search for Prior Art?
Value-Driven Patent Portfolio
Tracking Work History
How to Navigate BioSimilar Challenges
Standard for Getting a Patent
Rewards of the Practice
Patent Profile Analytics and Researchers
Value Management and Cash Flow
Cost of Registering a Trademark
The Advantage of Filing First
NDAs and Computer Codes
What is a Patent?
Patent Strategy Considerations
Benefits of Audit Action Sheet
"TM" Symbol
Broad Patent Claim
Biologics Price Competition and Innovation Act
Claim Abstraction Theory
Post-Grant Review
Factors That Make a Patent Valuable
Downside of Static Budget Allocation for Patents
Steps to Obtaining a Patent
Technical Background
Patent Owner Rights
Copyright
Experience
Tools for Auditing a Patent Portfolio
What Should a Company Understand at the End of an IP Audit?
Important Attributes to Being a Successful Patent Lawyer
Refused Trademark Recourse
Establishing Confidentiality
Pre-Litigation Challenges
Biologics vs Small Molecules
How Much Does it Cost to Get a Patent?
Challenges When Dealing with Patent Matters
PTAB Timing Trial Dynamics
Patent Citation Ranking
Becoming a Patent Lawyer
Hard Assets
Do Narrow Patents Add Value to a Portfolio?
Ideal Patent Strategy
Independent Claim vs Dependent Claim
What Makes Schwegman, Lundberg & Woessner Different?
Why Are Biologicals so Important?
How Big Should My First Patent Be?
What IP Should I Spend Money on First?
Joint Venture Ground Rules
Different Parts of a Patent Document
Improving Patent Portfolio Value
Impact of Post-Grant Proceedings
Considerations Before Hiring IP Council
Signing an NDA
Researching Competitors' IP
Freedom To Operate vs Clearance
Schwegman, Lundberg & Woessner - Chemicals and Pharmaceuticals
Risks of Not Patenting
Prior Art Challenge
Post-Grant Options and Estoppel
Third Party Confidentiality
What is a Trademark?
Types of Intellectual Property Protection
Requirements to Receive a Patent
"Claims" of a Patent
Equal Value Patents
Patent Examination Process
High Risk Joint Ventures
Patent Ownership and Patent Profile Analytics
Patent Portfolio and Budgets/Spending
Auction Audit Sheet - Key Issues to Address
Post-Grant Options and Cost
Assessing Executive Experience
Patent Trial and Appeal Board
Domain Registration Considerations
5 Year View Point
What Does an Audit Action Sheet Look Like?
PTAB Final Argument Trial Dynamics
Is There Still a Place for Traditional Re-Examination?
Improperly Marked Product
Inventorship vs Ownership
Impact of PTAB
Most Common Client Question
"Whats" - Audit Action Sheet
Trade Name Protection and Trademark Protection
Process for Registering a Trademark in the United States
Intent of Patent Laws
Advantages of Registering a Trademark
Provisional vs Non-Provisional Patent
Patents and Practicing an Invention
Is A United States Registered Trademark Effective in Other Countries?
Non-Disclosure Agreement
Managing OSS
Moderate Risk Joint Ventures
Provisional Patent
How Long Does an FTO Take?
Using Product Association with IP Assets
Patent Profile Analytics and Engineers
Limiting Issues Defined in District Court
How can OSS Negatively Affect a Company?
Practicing an Invention
Are BioSimilars Being Approved in the US?
Trademarks and Brand Value
Patent Analytics and Competition
Secondary Meaning of a Trademark
Outside of Law
Sponsor
What Doesn't a Patent Provide?
Patents and Other Forms of Intellectual Property Protection
Convergence Density
"Who" - Audit Action Sheet
Raising Good Prosecution Visibility
What is a BioSimilar Product Under US Law?
Confidential Information
Attorneys Not Understanding the Market
IP Registration Density
What is a Patent Portfolio?
Proper Way to Use a Trademark
Wasting Money on Low-Value Patents
Intellectual Property Protection
Office Action
Cost/Value Curve of Patent a Portfolio
Post-Grant Proceedings
Infringing on Another Patent
Claim Maps and BioSimilars
How is Schwegman Lundberg & Woessner Different?
FDA Guidelines for Demonstrating Biosimilarity
First Step in Performing a Patent Portfolio Audit
Trade Names vs Trademarks
Why Should Claims Not Be Read on the Prior Art?
Trademark
Schwegman Lundberg & Woessner & Post Grant Trial Practice
Attributes of a Good Patent
Engineers Not Understanding Patents
Infringement on the Rights of Other Patents
Golden Rule of Auditing a Patent Portfolio
Preventing "Genericide"
Patent Infringement
ITU
Helping In-House Council
Effective Stay Strategy
Repeating Competitor Audits
Litigation and BioSimilar Patenting
Attorneys and Patent Profile Analytics
The Different Types of Marks
Audit Action Sheet
Circle "R"
Evaluation Agreement and Computer Codes
Types of Inventions That Are Patentable
Picking a Domain Name
Merely Descriptive Refusal
How Does the Knowledge Gap Worsen Over Time?
Soft Assets
Two Main Value Drivers
Trade Dress
Traditional Re-Examination
Consequences of a Poorly Drafted Patent
Picking a Trademark
How is the Entire Patent Considered Prior Art?
Naming Problems with BioSimilars
How Do Patent Portfolio Values Become Concentrated over Time?
Seeking Money from Investors
Contractual Intellectual Property Rights
Inter Partes Review
Discovering Annuity Information
Impact of US Hatch Waxman Act 1984
Date of First Use
Renewing a Trademark Registration
How Should IP be Considered for Acquisition?
Post-Grant Options and Grounds of Challenge
How Does the Knowledge Gap Develop?
Calculating New Investments
Why Perform Risk Profile?
What Do I Give up in Getting My Patent?
When is a House like a Patent?
Joint Venture and Financial Agreements
Meet Mark Stignani
"How Much" - Audit Action Sheet
Risk Profile
Post-Grant Proceedings and Patent Enforcement
Get Your Assignments Straight - Contribution of Owners
Factors That Cause a Patent to Decline in Value
How Should IP be Considered for Growth?
Why Do You Enjoy Being a Lawyer?
Cost/Value Curve of a High Level Patent
A Less Expensive Alternative
Purposes of a Trademark
When to Do a Freedom to Operate
"SM" Symbol
Backward Citations
Inventors and Patent Analytics
How to Remedy Unwanted Disclosure of Confidential Information
Qualifying for a Patent
Risks of OSS
Goal of a Value-Driven Patent Portfolio
Demonstrating BioSimilarity Under U.S. Law
Budgeting for Drafting and Prosecution
Open Source Initiative
Rebutting a Merely Descriptive Refusal
Common Reasons Trademarks Are Rejected
Value Management and Risk Management
